USD10
DBVT acciones
Acerca de DBV TechnologiesDBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
USD10
DBVT acciones
Acerca de DBV TechnologiesDBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Estadísticas
VENTANA DE OPERACIÓN
Cerrado
ABRE A LAS
27 mar at 13:30 GMT+0
CAPITALIZACIÓN DE MERCADO
1169,70 M US$
PRECIO DE APERTURA
No hay suficientes datos
BAJO (1Y)
5,30 US$
ALTO (1Y)
26,19 US$
BAJO (24H)
19,51 US$
Alza (24H)
21,02 US$
Volumen (24 h)
7,83 mil US$
96,09 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | No hay suficientes datos | No hay suficientes datos |
1 día | 19,51 US$ | |
1 semana | 19,64 US$ |